Patients with persistently controlled atopic dermatitis continued to experience stable and low disease activity after receiving reduced dosages of dupilumab, according to a study published in Allergy.These findings show that patient-centered dosing regimens can be successful, Lotte S. Spekhorst, MD, of the department of dermatology and allergology and National Expertise Center for Atopic